On November 11, Grape King Bio announced its financial results for Q3, showing consolidated revenue of NT$2.9 billion, with after-tax net profit of NT$420 million, marking a 13.5% increase year-over-year. The company achieved an operating gross profit of NT$2.27 billion with a gross margin of 78.1%, and operating income rose 17.8% year-over-year to NT$750 million. Earnings per share (EPS) for the quarter reached NT$2.81, a 13.3% increase from the previous year. Both revenue and net income set historical records for the same period. For the first three quarters of 2024, Grape King Bio reported consolidated revenue of NT$8.01 billion (up 7.7% year-over-year), after-tax net profit of NT$1 billion (up 1.8%), an operating gross profit of NT$6.18 billion with a gross margin of 77.3%, and operating income of NT$1.74 billion (up 3.6%), with EPS at NT$6.76.
The company also disclosed consolidated revenue for October of NT$880 million, a year-over-year increase of 7%. Cumulative revenue for the first ten months reached NT$8.88 billion, up 7.6%. All three of its main business segments posted growth in October, with subsidiary Pro-Partner continuing its momentum, showing a 6.7% increase compared to last year and a 5.3% increase for the first ten months. As the peak sales season approaches, coupled with the launch of Pro-Partner’s annual “Health Festival—Buy Health, Get Rewards” event at the end of the month, revenue is expected to climb to new heights.
In mainland China, Shanghai Grape King saw slower demand for Double 11 restocking, leading to a softer outlook for its contract manufacturing business. Nonetheless, the segment still reported a 2.4% year-over-year growth, with cumulative revenue for the first ten months maintaining a robust 56.2% growth. Shanghai Grape King plans to actively pursue new contract manufacturing opportunities and strengthen its in-house brand operations by expanding new channels and launching health-oriented snacks. With a diversified growth strategy across contract manufacturing, distribution, and its own brands (including cross-border e-commerce), the company anticipates continued positive growth.
In Taiwan, Grape King Bio's October revenue rose 13.6% year-over-year, driven by strong orders from key domestic contract manufacturing clients, increased overseas raw material and finished product sales, and new pharmaceutical orders, leading to a 53% year-over-year surge in performance. Order scheduling now extends into Q1 of next year, setting the stage for exceptional revenue performance. Grape King’s own brands are also making strides in the retail beverage market, with the functional drink Kombucha 200P EX and a collaborative version of Kombucha with Malai Mole catching consumers’ attention through prominent in-store displays and channel promotions, driving a noticeable boost in sales. Leveraging the Double 11 shopping festival, the company is ramping up e-commerce and member engagement initiatives to support continuous revenue growth.
Resource (mandarin): 葡萄王Q3營收、獲利創歷史同期新高 再拚百億俱樂部
